VMAT 联用 RTOG 8502「QUAD shot」方案姑息治疗不可治愈头颈癌
94% 患者获总体缓解,中位 OS 5.7 个月,完成 3 周期与更好 OS 显著相关(P=0.002),无≥3 级急性或晚期毒性。
要点
- VMAT 实施 QUAD shot 方案总体缓解率 94%,肿瘤缓解率 85%。
- 完成全部 3 周期与更好 OS 显著相关(P=0.002)。
- 仅 12% 出现 2 级毒性,无≥3 级急性或晚期毒性。
核心结论
- VMAT 实施的 RTOG 8502「QUAD shot」方案对不可治愈头颈癌有效且毒性显著降低。
- 推荐完成多周期治疗以获得更好肿瘤缓解和/或生存。
研究设计与样本
- 放疗采用直线加速器 6 MV 光子 VMAT 计划,未行同期全身治疗。
主要发现
- 完成 1、2、3 周期者分别为 6 例(18%)、5 例(15%)、23 例(68%)。
- 肿瘤缓解 29 例(85%),26 例中症状缓解 20 例(77%),总体缓解 32 例(94%)。
- 接受≥2 周期者均达总体缓解;中位 OS 5.7 个月。
- 多因素分析显示完成全部 3 周期与更好 OS 显著相关(P=0.002)。
- 2 级毒性 4 例(12%),无急性≥3 级或晚期毒性。
关键数值与推荐
- 每周期方案:3.7 Gy/次,每日 2 次,间隔至少 6 h,连续 2 天共 4 次,总量 14.8 Gy。
- 每 3–4 周重复一周期,共 3 周期。
临床怎么用
- 对不可治愈头颈癌可采用 VMAT 实施 QUAD shot 姑息方案,毒性低。
- 在可耐受情况下尽量完成多周期(尤其 3 周期)以改善缓解与生存。
局限性
- 未设对照组,未行同期全身治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To review a single institutional experience of the Radiation Therapy Oncology Group (RTOG) 8502 "QUAD shot" regimen using volumetric modulated arc radiotherapy (VMAT) for incurable head and neck cancer (HNC). METHODS: Thirty-four consecutive patients with HNC were treated with at least one cycle of the RTOG 8502 regimen. Treatment plans included the use of VMAT with 6 MV photons generated by a linear accelerator. Two daily fractions of 3.7 Gy were delivered with an interval of at least 6 h for 2 consecutive days, totaling 14.8 Gy over 4 fractions. This was repeated every 3-4 weeks for a total of three cycles. No concurrent systemic therapy was performed. RESULTS: The number of completed cycles was 1 in 6 (18%) patients, 2 in 5 (15%), and 3 in 23 (68%). Tumor response was achieved in 29 (85%) patients and symptom relief in 20 (77%) of 26 patients. Overall response (tumor response or symptom relief) was achieved in 32 (94%) patients. All patients who received 2 or more treatment cycles achieved overall response. Median overall survival (OS) was 5.7 months. Multivariate analysis revealed that completion of all three treatment cycles was significantly associated with better OS (P = 0.002). Grade 2 toxicity was observed in four (12%) patients, but no acute Grade ≥ 3 or late toxicity was observed. CONCLUSIONS: The RTOG 8502 "QUAD shot" regimen using VMAT is effective for incurable HNC with highly reduced toxicity. Treatment with multiple cycles is recommended for better treatment response and/or survival.
引用
- Toya R, Saito T, Yamaguchi K, et al. Hypofractionated palliative volumetric modulated arc radiotherapy with the Radiation Oncology Study Group 8502 "QUAD shot" regimen for incurable head and neck cancer. Radiat Oncol. 2020. PMID: 32460865. doi:10.1186/s13014-020-01548-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。